

Special Issue

Antibiotic Resistance in Biomedicines

Message from the Guest Editors

Antibiotic resistance is now recognized as a major threat to human health, and it is considered a silent epidemic in the making. The rise of multidrug-resistant bacterial pathogens not only complicates the treatment of infectious diseases but also threatens medical procedures such as surgery, transplants, orthopedic implants, or chemotherapy, which depend on the prevention of infection. These routine procedures could become impossible if infection cannot be prevented using antibiotics. The fight against the rise and dissemination of multidrug-resistant bacteria must be tackled urgently, and it must be multidimensional. Public health measures must be taken to prevent an acceleration of bacterial acquisition of resistance to antibiotics in use. Research must be geared toward designing new classes of antibiotics and adjuvants that can overcome resistance to those in use. Multiple disciplines must come together to solve, or at least manage, this growing health emergency.

Guest Editors

Prof. Dr. María Soledad Ramírez

Department of Biological Science, California State University Fullerton,
800 N State College Blvd, Fullerton, CA 92831, USA

Prof. Dr. Marcelo E. Tolmasky

Department of Biological Science, California State University Fullerton,
800 N State College Blvd, Fullerton, CA 92831, USA

Deadline for manuscript submissions

closed (31 August 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/104225

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).